Article
Splicing-driven post-translational dysregulation: a new frontier for precision cancer medicine and immunotherapy.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico - 1 Jul 2026
Alatawi Sael
Abstract excerpt
Cancer is a disease marked by widespread molecular dysregulation, including alterations in gene expression, signaling pathways, and protein function. Among the critical regulators of protein function are post-translational modifications (PTMs), which fine-tune protein stability, activity, localization, and interactions. At the same time, more and more data has shown that mutations in parts of the splicing...
Topics
Join the communities discussing this publication.